Education
About Us
Working with TipRanks
Follow Us
Belite Bio, Inc. ADR (BLTE)
NASDAQ:BLTE
BLTE Stock Chart & Stats
$154.59
-$1.45(-2.47%)
At close: 4:00 PM EST
$154.59
-$1.45(-2.47%)
Day’s Range― - ―
52-Week Range$49.00 - $200.00
Previous CloseN/A
Volume15.47K
Average Volume (3M)64.23K
Market Cap
$6.08B
Enterprise Value$5.93B
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 19, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding37,514,630
10 Day Avg. Volume75,810
30 Day Avg. Volume64,229
Financial Highlights & Ratios
PEG Ratio63.44
Price to Book (P/B)13.21
Price to Sales (P/S)0.00
P/FCF Ratio-65.58
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-120.83
Forecast
1Y Price Target
$215.29Price Target Upside39.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$30.00M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase 3 DRAGON topline results demonstrated meaningful slowing of disease progression in Stargardt patients with good tolerability, supporting expectations for strong clinical adoption in a condition with no approved therapies.
Commercial Readiness And FormulationAn oral, once-daily tablet with favorable tolerability and management's commercial readiness plans, including a targeted sales force to increase genetic testing, could drive rapid patient identification and uptake at launch.
Regulatory ProgressRegulatory filings for tinlarebant in Stargardt disease, together with multiple expedited and orphan designations in major jurisdictions, could enable accelerated review paths and support approvals across key markets.
Bears Say
Financing And Cash Burn RiskPlanned substantial spending on research and commercialization could increase cash burn and may create a need for additional financing, diluting existing shareholders.
Payer Access And Pricing PressureHigh expected treatment cost may create payer hurdles that limit initial access and slow reimbursement despite the high unmet need in the rare pediatric population.
Regulatory Uncertainty And Potential DelaysA possible request from the U.S. regulator for an additional confirmatory trial would delay market entry and extend development timelines for the Stargardt indication.
Belite Bio, Inc. ADR News
BLTE FAQ
What was Belite Bio, Inc. ADR’s price range in the past 12 months?
Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $200.00 in the past 12 months.
What is Belite Bio, Inc. ADR’s market cap?
Belite Bio, Inc. ADR’s market cap is $6.08B.
When is Belite Bio, Inc. ADR’s upcoming earnings report date?
Belite Bio, Inc. ADR’s upcoming earnings report date is May 19, 2026 which is in 57 days.
How were Belite Bio, Inc. ADR’s earnings last quarter?
Belite Bio, Inc. ADR released its earnings results on Mar 02, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.546 by $0.166.
Is Belite Bio, Inc. ADR overvalued?
According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued.
Does Belite Bio, Inc. ADR pay dividends?
Belite Bio, Inc. ADR does not currently pay dividends.
What is Belite Bio, Inc. ADR’s EPS estimate?
Belite Bio, Inc. ADR’s EPS estimate is -0.64.
How many shares outstanding does Belite Bio, Inc. ADR have?
Belite Bio, Inc. ADR has 37,514,630 shares outstanding.
What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?
Belite Bio, Inc. ADR reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.546. Following the earnings report the stock price went down -6.684%.
Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?
Currently, no hedge funds are holding shares in BLTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Belite Bio, Inc. ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$215.29 (39.27% Upside)
$215.29 (39.27% Upside)
Hedge Fund Trend
Increased
By 233.8K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.62%
12-Months-Change
Fundamentals
Return on Equity
-34.29%
Trailing 12-Months
Asset Growth
143.82%
Trailing 12-Months
Company Description
Belite Bio, Inc. ADR
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Company Deck
BLTE Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was positive: the company reported a major clinical milestone (DRAGON Phase III success with 36% lesion-growth reduction), completed strong fundraising and set a clear regulatory and commercial timeline (rolling NDA in Q2 2026; target launch Q1 2027). The company is investing heavily in commercialization and R&D (reflected in sharply higher R&D and SG&A and wider net losses), and there are execution and timing risks around patient identification, pricing, ex-US filings and deprioritized programs. On balance the clinical success and cash runway materially de-risk the near-term path to approval and launch, outweighing the financial burn and execution risks described.View all BLTE earnings summariesBLTE Stock 12 Month Forecast
Average Price Target
$215.29
▲(39.27% Upside)
Technical Analysis
Denali Therapeutics
―
Kiniksa Pharmaceuticals
―
Beam Therapeutics
―
Harmony Biosciences Holdings
―
Centessa Pharmaceuticals
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
15.42% Other Institutional Investors
84.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---